WIF 1901
Alternative Names: WIF-1901Latest Information Update: 28 Aug 2024
At a glance
- Originator Whanin Pharmaceutical
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Parkinson's-disease in South Korea
- 24 Jul 2020 WIF 1901 is available for licensing as of 24 Jul 2020. https://www.whanin.com/_commonBase/content.php?co_id=outlicense_kor
- 24 Jul 2020 Early research in Parkinson's disease in South Korea (unspecified route) before July 2020 (Whanin Pharmaceutical pipeline, July 2020)